|
|||||
|
|
||||||
Originally published as JCO Early Release 10.1200/JCO.2007.14.1366 on April 7 2008 © 2008 American Society of Clinical Oncology. Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire
From the Hematology Department; Service de la recherche bio-médicale, Centre Hospitalier Universitaire, Hôtel-Dieu, Nantes; Hematology Department, Centre Hospitalier Universitaire Haut-Lévêque, Pessac; Hematology Department, Hôpital Necker-Enfants malades; Service de greffe de moelle osseuse, Hôpital Saint-Louis; Hematology Department, Hôpital de la Pitié-Salpetrière; Hematology Department, Hôpital Hôtel-Dieu; Hematology Department, Institut Curie, AP-HP, Paris; Unité de transplantation et de thérapie cellulaire, Institut Paoli-calmette, Marseille; Hematology Department, Medical University, Angers; Hematology Department, Centre Hospitalier Universitaire, Grenoble; Hematology Department, Hôpital Henri Mondor, AP-HP, Creteil; Hematology Department, Medical University, Nice; Hematology Department, Medical University, Lille; Hematology Department, Medical University, Toulouse; Hematology Department, Medical University, Clermont-Ferrand; Hematology Department, Institut Gustave-Roussy, Villejuif; and the Unité de Greffe de Moelle Osseuse, Centre Hospitalier Universitaire, Lyon, France Corresponding author: Steven Le Gouill, MD, PhD, Hematology Department, University Hospital, Hôtel-Dieu, Nantes, France; e-mail: steven.legouill{at}chu-nantes.fr Purpose Aggressive T-cell lymphomas (ATCLs) represent 10% to 15% of non-Hodgkin's lymphomas (NHLs) in adults. ATCLs show a worse prognosis than B-cell lymphomas. Patients and Methods On behalf of the Société Française de Greffe de Moëlle et de Thérapie Cellulaire, we conducted a retrospective analysis including 77 ATCL patients who underwent allogeneic stem-cell transplantation (alloSCT).
Results The different diagnosis included anaplastic large-cell lymphoma (ALCL; n = 27), peripheral T-cell lymphoma not otherwise specified (PTCL-NOS; n = 27), angioimmunoblastic T-cell lymphoma (AITL; n = 11), hepatosplenic Conclusion We conclude that alloSCT is a potentially efficient therapy for NK/T lymphomas and is worth further investigation through prospective clinical trials. published online ahead of print at www.jco.org on April 7, 2008 Authors disclosures of potential conflicts of interest and author contributions are found at the end of this article.
This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||
|
Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|